Cargando…
Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) affects 25% of the adult population globally. Since liver fibrosis is the most important predictor of liver-related complications in patients with NAFLD, identification of patients with advanced fibrosis among at-risk individuals is an important issue in cli...
Autores principales: | Irvine, Katharine M., Okano, Satomi, Patel, Preya J., Horsfall, Leigh U., Williams, Suzanne, Russell, Anthony, Powell, Elizabeth E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7858627/ https://www.ncbi.nlm.nih.gov/pubmed/33536476 http://dx.doi.org/10.1038/s41598-021-82315-z |
Ejemplares similares
-
Matrix Metalloproteinases-7 and Kidney Fibrosis
por: Ke, Ben, et al.
Publicado: (2017) -
Alcohol Consumption in Diabetic Patients with Nonalcoholic Fatty Liver Disease
por: Patel, Preya J., et al.
Publicado: (2017) -
Corrigendum: Matrix Metalloproteinase-7 and Kidney Fibrosis
por: Ke, Ben, et al.
Publicado: (2017) -
Predicting Liver‐Related Outcomes in People With Nonalcoholic Fatty Liver Disease: The Prognostic Value of Noninvasive Fibrosis Tests
por: Johnson, Amy L., et al.
Publicado: (2021) -
Prognostic Significance of Matrix Metalloproteinase‐7 (MMP‐7) Expression at the Invasive Front in Gastric Carcinoma
por: Liu, Xiu Ping, et al.
Publicado: (2002)